RecombiMAb anti-mouse PD-1 (CD279)

RecombiMAb anti-mouse PD-1 (CD279)

分享
品牌: BioXcell
pdf 下载产品说明书
pdf 下载SDS
用小程序,查商品更便捷
收藏
对比对比
咨询咨询
    来源宿主:
    产品介绍
    产品信息
    宿主
    克隆号
    RMP1-14-CP162

    Product Details

    The RMP1-14-CP162 monoclonal antibody is a chimeric version of the original RMP1-14 antibody. The variable domain sequences are identical to the original RMP1-14 but the constant region sequences have been switched from rat IgG2a to mouse IgG1. The RMP1-14-CP162 antibody contains no Fc mutations just as the original rat IgG2a antibody does not. RMP1-14-CP162 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.

    Specifications

    Isotype Mouse IgG1, κ
    Recommended Isotype Control(s)InVivoPlus mouse IgG1 isotype control, unknown specificity
    Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer
    Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
    Immunogen Syrian Hamster BKH cells transfected with mouse PD-1 cDNA
    Reported Applicationsin vivo blocking of PD-1/PD-L signaling*
    *Reported for the original rat IgG2a RMP1-14 antibody
    Formulation PBS, pH 7.0
    Contains no stabilizers or preservatives
    Endotoxin <1EU/mg (<0.001EU/μg)
    Determined by LAL gel clotting assay
    Aggregation <5%
    Determined by SEC
    Purity >95%
    Determined by SDS-PAGE
    Sterility 0.2 µm filtration
    Production Purified from CHO cell supernatant in an animal-free facility
    Purification Protein A
    RRIDAB_2927529
    Molecular Weight 150 kDa
    Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
    Hantavirus: Negative
    K Virus: Negative
    Lactate Dehydrogenase-Elevating Virus: Negative
    Lymphocytic Choriomeningitis virus: Negative
    Mouse Adenovirus: Negative
    Mouse Cytomegalovirus: Negative
    Mouse Hepatitis Virus: Negative
    Mouse Minute Virus: Negative
    Mouse Norovirus: Negative
    Mouse Parvovirus: Negative
    Mouse Rotavirus: Negative
    Mycoplasma Pulmonis: Negative
    Pneumonia Virus of Mice: Negative
    Polyoma Virus: Negative
    Reovirus Screen: Negative
    Sendai Virus: Negative
    Theiler’s Murine Encephalomyelitis: Negative
    Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
    组成成分
    程序性死亡蛋白抗体,磷酸盐缓冲液
    背景
    研究领域
    Cancer Biology, Immune Checkpoint Protein, Immunology
    声明 :本官网所有报价均为常温或者蓝冰运输价格,如有产品需要干冰运输,需另外加收干冰运输费。
    货号:
    CP162-1MG
    一键复制
    询价
    1mg
    5mg
    25mg
    50mg
    100mg
    选择数量
    当前规格1件起购 
    配送至
    预计2-3周送达,快递: 免运费,若需干冰额外收费